Document is current
Any future updates will be listed below
-
Authors
Perez, Edith A. https://orcid.org/0000-0001-7009-7467
de Haas, Sanne Lysbet
Eiermann, Wolfgang
Barrios, Carlos H.
Toi, Masakazu
Im, Young-Hyuck
Conte, Pier Franco
Martin, Miguel
Pienkowski, Tadeusz
Pivot, Xavier B.
Burris, Howard A. III
Stanzel, Sven
Patre, Monika
Ellis, Paul Anthony
- License Information
-
More Information
Article History
Received: 13 June 2019
Accepted: 13 June 2019
First Online: 24 June 2019
Competing interests
: EAP was a salaried employee of Genentech, Inc. at the time this work was prepared and owns stock in F. Hoffmann-La Roche Ltd. SLdH, SS, and MP are salaried employees of F. Hoffmann-La Roche Ltd. SS and MP own stock in F. Hoffmann-La Roche Ltd. WE has served as a consultant and on Speakers’ Bureaus for F. Hoffmann-La Roche Ltd. CHB has served as a consultant for F. Hoffmann-La Roche Ltd., Pfizer, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and Eisai and has received research funding from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, F. Hoffmann-La Roche/Genentech, Eisai, Lilly, Sanofi-Aventis, and Celgene. MT has received research funding from Chugai Pharmaceutical. PFC has served on Speakers’ Bureaus for Novartis, F. Hoffmann-La Roche Ltd., and AstraZeneca and has received research funding from F. Hoffmann-La Roche Ltd. and Novartis. MM has received honoraria from and has served as a consultant for F. Hoffmann-La Roche Ltd. TP has received honoraria and research funding from F. Hoffmann-La Roche Ltd., Pfizer, and Novartis. He has also served as a consultant for F. Hoffmann-La Roche Ltd. XBP has received honoraria from F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Amgen, Novartis, Pierre Fabre, and Eisai. He has also served as a consultant for F. Hoffmann-La Roche Ltd., Amgen, Novartis, Pierre Fabre, and Eisai. Y-HI, HAB, and PAE have nothing to disclose.
